{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Naltrexone+tablet&page=2",
    "query": {
      "intervention": "Naltrexone tablet",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Naltrexone+tablet&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T16:39:26.577Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02454712",
      "title": "Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF614",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone extended-release",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ensysce Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2016-11-16",
      "completion_date": "2018-01-18",
      "has_results": false,
      "last_update_posted_date": "2024-10-02",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02454712"
    },
    {
      "nct_id": "NCT02259179",
      "title": "Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)",
          "type": "DRUG"
        },
        {
          "name": "Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 80,
      "start_date": "2014-09",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2014-12-11",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02259179"
    },
    {
      "nct_id": "NCT01380093",
      "title": "Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nondependent Opioid Abuse, Episodic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "MS Contin (morphine sulfate, controlled release)",
          "type": "DRUG"
        },
        {
          "name": "EMBEDA (morphine sulfate / naltrexone hydrochloride)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 80,
      "start_date": "2011-02",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-05-31",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01380093"
    },
    {
      "nct_id": "NCT00992095",
      "title": "Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid-Related Disorders"
      ],
      "interventions": [
        {
          "name": "buprenorphine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roxane Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2006-08",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2018-01-23",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00992095"
    },
    {
      "nct_id": "NCT04604704",
      "title": "Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Long COVID-19",
        "Post-COVID-19 Syndrome"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "NAD+",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "AgelessRx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2021-01-28",
      "completion_date": "2023-01-23",
      "has_results": false,
      "last_update_posted_date": "2023-01-25",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04604704"
    },
    {
      "nct_id": "NCT03078075",
      "title": "Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Methamphetamine Use Disorder"
      ],
      "interventions": [
        {
          "name": "Naltrexone: Vivitrol®",
          "type": "DRUG"
        },
        {
          "name": "Placebo (PLB) Injectable",
          "type": "DRUG"
        },
        {
          "name": "Bupropion: Wellbutrin XL®",
          "type": "DRUG"
        },
        {
          "name": "Placebo (PLB) Oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 403,
      "start_date": "2017-05-05",
      "completion_date": "2019-07-25",
      "has_results": true,
      "last_update_posted_date": "2021-05-03",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03078075"
    },
    {
      "nct_id": "NCT02978417",
      "title": "Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Naltrexone for extended-release injectable suspension",
          "type": "DRUG"
        },
        {
          "name": "Oral naltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2017-09-21",
      "completion_date": "2019-06-30",
      "has_results": true,
      "last_update_posted_date": "2020-06-16",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 1,
      "location_summary": "Raleigh, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978417"
    },
    {
      "nct_id": "NCT00711477",
      "title": "A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Naltrexone SR 32 mg/bupropion SR 360 mg/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "fMRI scan",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Orexigen Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 46,
      "start_date": "2008-09",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2015-01-06",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 1,
      "location_summary": "Upton, New York",
      "locations": [
        {
          "city": "Upton",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00711477"
    },
    {
      "nct_id": "NCT06140420",
      "title": "Naltrexone for Prolonged Grief Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Naltrexone HCl 50 MG Oral Tablet",
        "Placebo"
      ],
      "interventions": [
        {
          "name": "Naltrexone Oral Product",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Tech University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 7,
      "start_date": "2023-08-01",
      "completion_date": "2025-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 1,
      "location_summary": "Lubbock, Texas",
      "locations": [
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06140420"
    },
    {
      "nct_id": "NCT00000450",
      "title": "Naltrexone Maintenance Treatment of Alcoholism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Alcoholism"
      ],
      "interventions": [
        {
          "name": "Naltrexone Tablet",
          "type": "DRUG"
        },
        {
          "name": "Matched Placebo Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Scripps Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 159,
      "start_date": "1997-04-10",
      "completion_date": "2002-02-13",
      "has_results": false,
      "last_update_posted_date": "2017-04-20",
      "last_synced_at": "2026-09-23T16:39:26.577Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000450"
    }
  ]
}